Original Research

Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis

Xu W, Kuang M, Gong Y, Cao C, Chen J, Tang C

OncoTargets and Therapy 2016, 9:4833-4842

Published Date: 4 August 2016